Albany, Costantine
Dockter, Travis
Wolfe, Eric
Le-Rademacher, Jennifer
Wagner-Johnston, Nina
Einhorn, Lawrence
Lafky, Jacqueline M.
Smith, Ellen
Pachman, Deirdre
Staff, Nathan
Ma, Cynthia
Loprinzi, Charles L.
Costello, Brian A.
Funding for this research was provided by:
National Cancer Institute (UG1CA189823, UG1CA233160, UG1CA233196, UG1CA233339, UG1CA232760)
Article History
Received: 28 February 2020
Accepted: 19 May 2020
First Online: 4 June 2020
Change Date: 4 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00520-021-06523-z
Compliance with ethical standards
:
: Dr. Einhorn owns Amgen and Biogenidec stock; Dr. Loprinzi reports personal fees from PledPharma, personal fees from Disarm Therapeutics, personal fees from Asahi Kasei, personal fees from Metys Pharmaceuticals, personal fees from OnQuality, personal fees from NKMax, and personal fees from Mitsubishi Tanabe, outside the submitted work; Dr. Wagner-Johnston reports personal fees from Regeneron, ADC Therapeutics, CALIB-R, Verastem, outside the submitted work; None of the other authors noted any potential conflicts of interest.
: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.